Thalassemia Clinical Trials and Treatments

Thalassemia is an autosomal recessive hemoglobinopathy caused by mutations in genes encoding alpha or beta globin chains, resulting in reduced or absent hemoglobin production. The imbalance of globin chains causes hemolysis (destruction of red blood cells) and ineffective erythropoiesis (impaired red blood cell production). In beta-thalassemia major, the most severe form, hemoglobin production is virtually absent, resulting in severe hemolytic anemia requiring regular blood transfusions to maintain acceptable hemoglobin levels.

The most common symptoms of Thalassemia include Severe anemia and fatigue, Jaundice from hemolysis, Bone pain and deformities from extramedullary hematopoiesis, Hepatosplenomegaly, Heart problems from iron overload, among others. Thalassemia affects approximately 1 in 100,000 people in the U.S.; higher in Mediterranean and Asian populations. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Thalassemia from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Thalassemia research has produced FDA-approved gene therapies for beta-thalassemia, while no gene therapy is yet approved for alpha-thalassemia. Research continues improving delivery methods and safety profiles.

Yes. As of September 2026, Trial Friend lists 4 FDA-approved drugs used to treat Thalassemia: Reblozyl (luspatercept), first approved in 2019; Zynteglo (betibeglogene autotemcel), first approved in 2022; Casgevy (exagamglogene autotemcel), first approved in 2023; and Aqvesme (mitapivat), first approved in 2025.

Each has its own page with what the label covers, side effects and how it is given, and the Treatments section of this page adds any further approved drugs found in FDA labeling data.

Thalassemia is caused by variants in the HBB, HBA1 and HBA2 genes. Beta thalassemia is HBB; alpha thalassemia is usually deletion of one to four HBA1/HBA2 alleles, so testing must include deletion analysis.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child. The condition affects approximately 1 in 100,000 people in the U.S.; higher in Mediterranean and Asian populations. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Thalassemia looks at the HBB, HBA1 and HBA2 genes. Beta thalassemia is HBB; alpha thalassemia is usually deletion of one to four HBA1/HBA2 alleles, so testing must include deletion analysis.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Thalassemia clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Thalassemia clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.